Respiratory Syncytial Virus (RSV) Vaccine

Respiratory syncytial virus (RSV) is a prevalent, contagious respiratory pathogen, the leading cause of bronchitis and pneumonia, affecting more than 64 million people each year worldwide. In vulnerable patients (infants and elderly) it can cause significant morbidity and mortality. Currently there is no vaccine available in the market and the only prophylaxis is a monoclonal Ab (palivizumab) restricted to high-risk pediatric patients. With V-306 Virometix offers a differentiated approach to RSV vaccine development. Our vaccine candidate – already in clinical phase I – demonstrates strong, durable, specific and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease (VAERD).